Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC010139 | Panoply™ Human NAT2 Knockdown Stable Cell Line | Inquiry |
| CSC-DC013435 | Panoply™ Human RNF38 Knockdown Stable Cell Line | Inquiry |
| CSC-DC014546 | Panoply™ Human SLC38A1 Knockdown Stable Cell Line | Inquiry |
| CSC-SC010139 | Panoply™ Human NAT2 Over-expressing Stable Cell Line | Inquiry |
| CSC-SC013435 | Panoply™ Human RNF38 Over-expressing Stable Cell Line | Inquiry |
| CSC-SC014546 | Panoply™ Human SLC38A1 Over-expressing Stable Cell Line | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD10541Z | Human NAT2 adenoviral particles | Inquiry |
| AD13891Z | Human RNF38 adenoviral particles | Inquiry |
| AD14960Z | Human SLC38A1 adenoviral particles | Inquiry |
| LV19136L | human NAT2 (NM_000015) lentivirus particles | Inquiry |
| LV24191L | human RNF38 (NM_194329) lentivirus particles | Inquiry |
| LV24192L | human RNF38 (NM_194330) lentivirus particles | Inquiry |
| LV24193L | human RNF38 (NM_022781) lentivirus particles | Inquiry |
| LV25825L | human SLC38A1 (NM_001077484) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH216785 | shRNA set against Human NAT2(NM_000015.2) | Inquiry |
| SHH221712 | shRNA set against Human SLC38A1(NM_001077484.1) | Inquiry |
| SHH349496 | shRNA set against Mouse NAT2 (NM_010874.3) | Inquiry |
| SHH410928 | shRNA set against Rat SLC38A1 (NM_138832.1) | Inquiry |
| SHR187032 | shRNA set against Human RNF38(NM_022781.4) | Inquiry |
| SHR186996 | shRNA set against Human RNF38(NM_194328.2) | Inquiry |
| SHR186954 | shRNA set against Rat Rnf38(NM_134467.1) | Inquiry |
| SHR186916 | shRNA set against Human RNF38(NM_194329.2) | Inquiry |
| SHH410924 | shRNA set against Mouse SLC38A1 (NM_134086.4) | Inquiry |
| SHH397320 | shRNA set against Rat RNF38 (NM_134467.1) | Inquiry |
| SHR205644 | shRNA set against Rat Slc38a1(NM_138832.1) | Inquiry |
| SHH397316 | shRNA set against Mouse RNF38 (NM_175201.5) | Inquiry |
| SHH397312 | shRNA set against Human RNF38 (NM_194332.2) | Inquiry |
| SHH349500 | shRNA set against Rat NAT2 (NM_053854.1) | Inquiry |
| SHH349492 | shRNA set against Human NAT2 (NM_000015.2) | Inquiry |
| SHH216803 | shRNA set against Rat Nat2(NM_053854.1) | Inquiry |
| SHH410920 | shRNA set against Human SLC38A1 (NM_030674.3) | Inquiry |
| SHW003358 | shRNA set against Chicken SLC38A1 (NM_001199603) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCR380617 | Rat Nat2 ORF Clone(NM_053854.1) | Inquiry |
| MiUTR1R-07003 | RNF38 miRNA 3'UTR clone | Inquiry |
| MiUTR1R-04121 | NAT2 miRNA 3'UTR clone | Inquiry |
| MiUTR1H-09553 | SLC38A1 miRNA 3'UTR clone | Inquiry |
| MiUTR1H-08904 | RNF38 miRNA 3'UTR clone | Inquiry |
| MiUTR1H-08903 | RNF38 miRNA 3'UTR clone | Inquiry |
| CDFR014260 | Rat Slc38a1 cDNA Clone(NM_138832.1) | Inquiry |
| CDFR013585 | Rat Nat2 cDNA Clone(NM_053854.1) | Inquiry |
| CDFR013501 | Rat Rnf38 cDNA Clone(NM_134467.1) | Inquiry |
| CDFH017907 | Human SLC38A1 cDNA Clone(NM_001077484.1) | Inquiry |
| CDFG012497 | Human RNF38 cDNA Clone(NM_194332.2) | Inquiry |
| CDFG003949 | Human RNF38 cDNA Clone(NM_022781.4) | Inquiry |
| MiUTR1R-07470 | SLC38A1 miRNA 3'UTR clone | Inquiry |
| MiUTR3H-12334 | NAT2 miRNA 3'UTR clone | Inquiry |
| CDCL185431 | Human NAT2 ORF clone(NM_000015.2) | Inquiry |
| CDCR325298 | Human RNF38 ORF Clone(NM_194330.2) | Inquiry |
| CDCB180292 | Rabbit NAT2 ORF clone (NM_001082186.1) | Inquiry |
| CDCB183317 | Rabbit SLC38A1 ORF clone (XM_008259626.1) | Inquiry |
| CDCB193671 | Rabbit RNF38 ORF clone (XM_008266062.1) | Inquiry |
| CDCH074650 | human RNF38 ORF clone (NM_194329.2) | Inquiry |
| CDCH074652 | human RNF38 ORF clone (NM_022781.4) | Inquiry |
| CDCH074656 | Mouse Rnf38 ORF clone (NM_001038993.3) | Inquiry |
| CDCH400977 | Mouse SLC38A1 ORF clone(NM_001166458.1) | Inquiry |
| CDCR241101 | Mouse Slc38a1 ORF Clone(NM_001166456.1) | Inquiry |
| CDCR241907 | Mouse Nat2 ORF Clone(NM_001168577.1) | Inquiry |
| CDCR249461 | Mouse Nat2 ORF Clone(NM_010874.3) | Inquiry |
| CDCS417756 | Human RNF38 ORF Clone (BC033786) | Inquiry |
| CDCS407226 | Human SLC38A1 ORF Clone (BC010620) | Inquiry |
| CDCS405354 | Human NAT2 ORF Clone (BC015878) | Inquiry |
| CDCR381307 | Rat Slc38a1 ORF Clone(NM_138832.1) | Inquiry |
| CDCR381253 | Rat Rnf38 ORF Clone(NM_134467.1) | Inquiry |
| CDCR265921 | Mouse Slc38a1 ORF Clone(NM_134086.4) | Inquiry |
| CDCR345188 | Human SLC38A1 ORF Clone(NM_001077484.1) | Inquiry |
| CDCR325300 | Human RNF38 ORF Clone(NM_194332.2) | Inquiry |
| CDCR272691 | Mouse Rnf38 ORF Clone(NM_175201.5) | Inquiry |
| CDCB164833 | Chicken SLC38A1 ORF Clone (NM_001199603) | Inquiry |
The N-acetyltransferase 2 gene (NAT2) is located in the short arm 2 region 2 (8p22) of human 8th pair of chromosomes. The coding region is 870 bp long and encodes the drug phase II metabolic enzyme N- Acetyltransferase. There are mainly 7 mutations in the NAT2 gene polymorphism, and some site mutations will directly lead to changes in the activity of the encoded metabolic enzymes, which may affect the inactivation or activation of some drug metabolism and carcinogens, thus leading to some drug-related diseases and cancers occur.
The Role of NAT2
NAT2 is widely found in many organelles in the human body. It has different degrees of expression in the liver, large intestine, small intestine, stomach, lung, prostate, larynx, bladder, esophagus, etc., and is dominant in liver and intestinal epithelial cells. The study found that the activity and the expression decreased in the order of duodenum, jejunum, ileum, colon and rectum, and there were differences between different populations and individuals. Differences in tissue-specific expression make the NAT2 genotype have different effects on different organs and tissue carcinogenesis. At present, the common allelic mutations occur mainly at seven sites, such as 191, 282, 341, 481, 590, 803, and 857. Among them, the mutations of Asians 481, 590, 857, and 191 are the most common. According to the acetylation ability, the NAT2 gene phenotype can be divided into fast acetylation type, intermediate type and slow acetylation type.
Aromatic amines and heterocyclic amines are found in tobacco, high-temperature cooked meats, pharmaceuticals, and certain chemical raw materials and products. They have been identified as one of the former carcinogens. The acetylation process in which NAT2 participates in the catalysis is an important part of the metabolism of this substance in the body. It is generally believed that aromatic amines (heterocyclic amines) enter the human body, first catalyzed by cytochrome P450 in the liver to form N-hydroxyaromatic amines (heterocyclic amines), and then form N-acetyl aromatic under the catalysis of NAT2. The latter contains highly reactive N ions, which are easily incorporated into DNA to form DNA adducts, causing DNA mutations and cell carcinogenesis. When the NAT2 gene is mutated, it may cause changes in enzyme activity or quantity, and may also cause an increase in enzyme instability, thereby increasing the N-acetoxy-based product and inducing canceration.
Figure 1. Dual functions of NAT2 in bladder carcinogenesis. (Quan, L., et al. 2016)
The Relationship between NAT2 and Disease
The occurrence of a mutation in the NAT2 allele often results in decreased enzyme activity, decreased stability, and decreased expression. This impairs the ability of acetylation to metabolize, resulting in differences in individual susceptibility to disease. The distribution of NAT2 gene polymorphism is closely related to liver damage caused by anti-tuberculosis drugs. A study of 241 Indonesian tuberculosis patients (50 patients with liver injury and 191 patients without liver injury) found that slow-acetylation (NAT2* 6) and anti-tuberculosis drug-induced liver damage (anti- tuberculosis drug - induced Hepatic injury, ADIH) related. The risk of ADIH in NAT2 slow acetylation is 3.45 times higher than that of fast acetylation and intermediate acetylation. Studies have shown that the slow acetylation of NAT2 is a high risk factor for drug-induced liver injury in tuberculosis patients. NAT2 is the most well-recognized gene in the susceptibility gene for anti-tuberculosis drugs. It is the main metabolic enzyme of isoniazid and rifampicin, which affects the metabolism of isoniazid and rifampicin. During isoniazid metabolism, isoniazid is first acetylated by NAT2 to acetyl isoniazid and then hydrolyzed to produce monoacetylhydrazine.
References: